Slingshot Insights is the first crowdfunded expert network and due diligence community. Members use our suite of tools to cut through the noise and Become the Smart Money. We provide you affordable access to Experts and Management Teams so that you can make informed investment decisions. By grouping investors around project ideas they care about, we pass along significant savings without compromising on quality.
Please note that the article that you are reading here was originally written on my blog and is republished in Seeking Alpha and other forums. Consequently, I neither track nor respond to comments here. I am sorry! ================ Editors' Note: Seeking Alpha monitors Dr. Damodaran blog and posts relevant articles on his behalf.
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
I am Semi-retired as a consultant (40+ years) in the fields of applied Pharmacology/Toxicology and Occupational Health & Safety, dealing with the role of drugs and chemicals in disease pathology and its treatment, complex exposure situations (use of medications, drugs of abuse & addiction and exposure to toxic workplace chemicals), toxicity and drug/chemical interactions and related management challenges.
I am now delving into the investment world for hobby and to increase retirement resources using my own capabilities and the many resources available. I am a novice investor and looking to learn at my pace and with assistance from others. I have strong scientific (pharmacology & health) and analytical training, experience and perspective. I have formal Risk Management training and experience and will use that to guide my investing decisions.
From an investment perspective, I am looking for a combination of stable and proven income generating companies, balanced with managed risk associated with biotechnology equities with large upside potential, ones leading the charge into research and development of ground breaking biological solutions to society' needs. I plan to focus on the biotechnology sector as that is where my strength lies. I look forward to learning from the SA contributors and where appropriate making a contribution with my perspective and views.
Former broker, now an independent analyst/writer on Seeking Alpha and founder and editor of the Growth Stock Forum. Focusing on small-cap, mid-cap and biotech stocks. Looking for substantial sales and earnings growth potential and seeking the best risk-adjusted returns from my stock selection. Taking advantage of medium to long-term momentum.
My articles represent my personal opinion and analysis and should not be regarded as investment advice in any way. Readers and subscribers should do their own due diligence and/or consult their financial advisor before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.
Exclusive research: http://seekingalpha.com/author/oneil-trader/research
Grant Zeng has over 10 years of professional experience in equity research and analysis. Grant joined Zacks Investment Research Inc. in March 2006, and currently is a senior equity analyst covering biotech/pharma industry. Before joining Zacks, Grant worked for TheStreet.com as a biotech analyst from 2005-2006. From Sept 2001 to December 2003, Grant worked for China Pacific Insurance Co. as an senior equity/fund analyst. Grant was a healthcare equity analyst with Young & Partners, LLC from Aug 2000 to September 2001. Grant had also teaching and researching experience in pharmaceutical science.
Grant Zeng obtained his MBA with a major in Finance in 2000 from McMaster University, Canada. He also holds a Master of Science in Biochemistry from the University of Western Ontario, Canada; Master of Pharmacology and Bachelor of Medicine from Second Military Medical University, China.
Grant Zeng is a Chartered Financial Analyst (CFA) charter holder.
Tom Shaughnessy is owner of SecretCaps.com, an independent investor and analyst. He has been investing in the stock market since the age of twelve. His style is comprehensive and includes multi-layered research on a concentrated set of stocks. Tom enjoys constructive dialogue regarding various investment ideas and theories.
Tom enjoys intensive research on prospective investments. This includes valuation estimates and modeling, CEO and management interviews, product and expansion overviews, future prospects, financial analysis and the current state of affairs at the company. Moreover, Tom's articles have a focus on micro-cap companies whose potential have flown under the radar.
In his leisure time Tom enjoys playing racquetball on a competitive level.
HFI Research Premium Subscribers get 5 weekly reports: HFI Portfolio Weekly Update, Natural Gas Weekly Outlook, Oil Markets Weekly Outlook, Weekly Rant (investment topics), Big Picture Outlook.
Our TipRank profile: https://www.tipranks.com/bloggers/hfi
Daniel B. Ravicher is a registered patent attorney who frequently consults with investment banks, hedge funds, and individual investors on legal issues that may materially affect the value of publicly traded companies. In addition to private consulting, Mr. Ravicher also regularly publishes articles covering such issues. He is not an investment adviser and the opinions expressed are not legal, financial or any other kind of advice.
In his legal practice, Mr. Ravicher provides transaction and litigation legal services to clients with respect to a wide range of technologies, including pharmaceuticals, biotechnology, software, the Internet, mobile devices, mechanical devices, consumer products and business methods. He represented the successful plaintiffs in the Supreme Court case invalidating patents on human genes and has twice testified before Congress on the topic of patent reform. Repeatedly named one of 'The 50 Most Influential People in IP' by Managing Intellectual Property and named Appellate Lawyer of the Week by the National Law Journal, Mr. Ravicher has appeared as a guest on national television, been quoted in articles by the Wall Street Journal, Bloomberg, the New York Times, the Financial Times and other publications, and spoken at dozens of national and international conferences on issues relating to patent and technology law.
Mr. Ravicher received his law degree from the University of Virginia School of Law, where he was the Franklin O'Blechman Scholar of his class, a Mortimer Caplin Public Service Award recipient and an Editor of the Virginia Journal of Law and Technology, and his bachelors degree in materials science magna cum laude with University Honors from the University of South Florida. He is admitted to the United States Supreme Court, the Courts of Appeals for the Federal, 2nd and 11th Circuits, the District Courts for the Southern and Eastern Districts of New York and the Southern and Middle Districts of Florida, the States of New York and Florida, and the United States Patent and Trademark Office.
Markman Advisors specializes in the strategic analysis of investment opportunities presented by intellectual property—and in particular, patent—litigation activities. We are all USPTO-registered patent attorneys with decades of combined experience in patent litigation, licensing and procurement. After many years practicing at some of the world’s largest and well-known law firms, we established and now run a premier intellectual-property boutique law firm, where we continue to practice patent litigation.
We have litigated numerous high-stakes patent cases in federal district courts throughout the country, as well as at the appellate level before the Federal Circuit. We are also experienced in USPTO proceedings, and have advised clients across a wide swath of technical areas with respect to patent-related matters.
Our base of former and current legal clients is diverse, from technology start-ups to some of the world’s largest and most well-known corporations. Collectively, we have led those clients through numerous Markman hearings, summary judgment motions, trials and appeals – on both the offensive and defensive sides of a case.
Our patent litigation experience, coupled with our knowledge of the market for "patent play" stocks, is the alpha we bring to each patent litigation-driven investment opportunity.
My investment work is strictly non-professional. I seek to maximize value by developing data-rich, bottom-up models that forecast future company performance based on prior history. I focus on companies in the energy sector that deliver value to investors through regular distributions.
Professionally, I'm an engineer with experience in statistical process analysis.
A frequent source for shows on Fox Business and CNBC, Matt Gohd serves as an experienced financial commentator. Most recently, he has shared his thoughts on the effect of the 2012 presidential election on the markets and the impact of the Greek debt crisis. Mr. Gohd has worked in financial markets for 35 years and has seen numerous boom and bust cycles. This experience allows him to gauge market shifts and take a contrarian perspective. Matt Gohd often analyzes trends related to supply and demand in the market based on underlying micro- and macroeconomic factors.
Matt Gohd currently acts as strategist and Senior Managing Director at Wallach Beth Capital New York City. As such, he assists a variety of investors, such as hedge funds and family offices, in risk management. He holds extensive experience with options, including conducting research and trading. In addition, Mr. Gohd earned licenses for series 7, 69, 63, and 24.
In the past, Matt Gohd chaired Bluestone Capital, which originated numerous managed public offerings totaling more than $1 billion. Before its 2001 sale, Bluestone assisted entities in the retail, technology, biotechnology, and Internet sectors. Mr. Gohd has also served on the executive committees of the boards for Onstage Entertainment, Iconic Brands, and eDiets.com.
In 1987, Mr. Gohd advised the chairman of the Congressional committee investigating the stock market’s October crash. He continued his connection to government officials by working with President Bill Clinton during both his campaigns and acting as a Managing Trustee for the Democratic National Committee.
Before relocating to the East Coast, Mr. Gohd studied finance and statistics at California State University, East Bay.
I'm a professor and data scientist who has developed scorecards to detect fraudulent bank transactions. As an investor I look for fraudulent stocks and other stocks that aren't what they seem.
I worked in New York's financial sector for almost exactly 20 years, mostly as a healthcare analyst (drugs, biotech, and medical devices), but also as an assistant research director, portfolio manager, and options strategist. My last formal job had me in charge of Value Line's premium priced "Select" and "Special Situation" products. The former highlights the company's top stock pick of each month and the latter introduces relatively small companies. I quit that job in June, 2009 for reasons that a dozen or so confidentiality agreements preclude my discussing. In September of that year, I launched 3DimensionalResearch.com (3DR), which allows me to continue doing what I was doing previously.
I am a strong believer in maximum transparency, in both personal and business relationships. So, in that vein:
A google search will show that my former employer sued 3DR and me in November, 2009 for copyright infringement, hot news misappropriations, and the proverbial kitchen sink. Although a search won't show this, unfortunately, I represented myself in a federal courtroom in December and, in accordance with the judge's instructions, the case was settled in a matter of minutes.
Additional Disclosure: 3DR has been a financial failure thus far, in terms of getting subscribers. I detest marketing and few people want to pay for information anymore, least of all from a no-name website. That said, the vast majority of my recommendations have done very well and my personal portfolio is doing extraordinarily well (65.5% in 2013) since I tend to follow most of my own recommendations, the "event driven special situations," in particular.
I retired as CEO of an Automotive Parts supplier, and manage an investment portfolio for myself and family. I have a BA in History from Royal Military College of Canada and an MBA from the University of Western Ontario. My first career was as a fighter pilot in the RCAF, and, following my MBA I joined McKinsey & Company, Inc. leaving them for Canadian GE. I left CGE as a Vice President in 1984 and founded The Enfield Corporation Limited ("Enfield") which grew from 243 employees in 1984 to over 10,000 in 1989 when Enfield was taken over and I was replaced as CEO. In 1989, I acquired control of Algonquin Mercantile Corporation, renamed Automodular Corporation in the late 1990's when I turned it to focus exclusively on automotive parts sub-assembly. Along the way, Algonquin turned a few ageing drug stores into Pharmx Rexall Drug Stores Ltd., sold to Katz group in 1997 and today a major Canadian drug store chain. I have been a private investor since 1971 both directly and through a private company controlled by myself and members of my family.
Friedrich is the name given to our algorithm for analyzing companies that trade on the global stock markets. In creating Friedrich we concentrated on analyzing each company’s Main Street operations through various established ratios, along with our own unique ratios that we developed over the last 30 years. What we came up with is a final "Main Street" price per share based on Generally Accepted Accounting Principles (GAAP), which is a framework of accounting standards, rules and procedures defined by the professional accounting industry, which has been adopted by nearly all publicly traded U.S. companies. We feel that our Main Street price result is what each company would need to trade at in order to be attractive to a businessperson on Main Street looking to buy at a bargain.
Since the only constant in the universe is change, the results for each company fluctuate by varying degrees. No company is an island unto itself, but each operates in a world of constant change and at times in areas where Chaos is the norm. By analyzing a company’s Main Street operations over time, Friedrich is able to give the potential investor a decade long analysis (opinion) as well as offering a Trailing Twelve Month (TTM) analysis (opinion), as well. Thus our readers will not only get as close to a real time view of operations on Main Street as is possible, but then can measure the consistency of the company’s operations over time to determine if s/he should invest or not.
Through our Friedrich algorithm we can analyze ten years of Balance Sheet, Income Statement and Cash Flow Statement data for each company all at once and generate one final result in seconds. Friedrich was designed to be ultra-conservative and thus will cut zero slack to any company under analysis and will do so with zero emotion. Companies must be exceptional in order to get an attractive Main Street valuation and the ideal investments according to our backtesting are the ones that have been consistent over time.
By being so ultra conservative Friedrich is designed to identify bargains that Wall Street investors may have overlooked. Companies shares may trade on the stock market but the companies themselves operate on Main Street, so Friedrich is designed to generate a Main Street price per share first and only then does he go to Wall Street and see the price for which Benjamin Graham’s “Mr. Market” is offering the shares.
Ashraf Eassa is a technology specialist with The Motley Fool. He writes mostly about technology stocks, but is especially interested in anything related to chips -- the semiconductor kind, that is.
Currently working as an Equity Analyst, where I focus on investment idea generation through detailed financial analysis and company contact.
Prior to this, I was working as an investment analyst responsible for idea generation at a boutique small cap equities manager.
Amongst other responsibilities, I focus was on generating investment ideas using fundamental and technical analysis as well as detailed financial modeling. I holds a Bachelor of Commerce (Finance and Econometrics) and a candidate for the Level III examination of the Chartered Financial Analyst program and the Level II examination of the Chartered Alternative Investment Analyst program.
We are a research group that consults hedge fund and high-net worth clients. We specialized in identifying special opportunities from both the long and short side. The writer for 3D Analytics has professional traded for hedge funds for 10+ years and specializes in 1) finding hidden, unrecognized value, 2) shorting overvalued stocks, and 3) arbitrage situations. The articles are written solely by him, but has a group that assist him in finding opportunities, basic research, and editing.
Portfolio manager delivering alpha principally through the discovery of under-the-radar small cap names with compelling stories misunderstood/underappreciated by the market.
Retired Timber Company executive with experience in both the Southeast and the Northwest. I have worked for timber companies in Alabama, Georgia, North Carolina, South Carolina, and Washington state. I have experience in timber management, wood procurement, timberland acquisitions and dispositions, and timberland consulting.
Fredrik Arnold is my pen name. In 2012 I retired from doing quality service analysis for John Hancock Long Term Care Insurance in Boston then moved to North Carolina in 2013. My fascination with capital preservation, fixed fractional trading, and trading systems keeps me blogging for Seeking Alpha. Most of my articles focus on dividend yields and analyst mean 1 yr targets as stock trading indicators. These are essential tools for catching the most valuable dividend dogs.
I hold a Bachelor’s in Banking and Information Systems from Curtin University, Perth Australia; a Master’s degree in Financial Analysis from La Trobe University, Melbourne Australia; and I’m currently undertaking the CFA accreditation having taken the CFA Level 2 exam in June 2014.
Currently I'am working as a Fund Performance Analyst at a leading custodian bank in Melbourne, Australia. Prior to my current role I was an Investment Analyst at a private equity firm headquartered in Bahrain. During my time as an Investment Analyst I conducted financial research and analysis unlisted assets, built complex financial models on excel, performed valuations and simulation analysis, participated in the due diligence process (buy and sell side transactions), prepared investment reports and presentations for top tier management, investors, government, and HNW individuals.